The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.

Once the efficacy and safety data were obtained from participants administered ABT-450/r + ABT-530 + RBV weight-based (Arm 1) in Study M14-213, the decision was made to end this study before subjects were enrolled into Arm 2.

Inclusion Criteria:

• Male or female (of non-child bearing potential) between 18 and 70 years of age with Body Mass Index ≥18 to <38 kg/m2.
• Chronic HCV genotype 3 infection prior to study enrollment and has never received antiviral treatment for HCV.
• Subject has plasma HCV RNA level > 10,000 IU/mL at Screening.
• Sexually active males must be sterile, have male partners only, or agree to use two effective forms of birth control for 7 months after stopping study drug.

Exclusion Criteria:

• History of severe, life-threatening or other significant sensitivity to any drug.
• Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab).
• Prior therapy for the treatment of HCV.
• Any current or past clinical evidence of cirrhosis.
• Any cause of liver disease other than chronic HCV-infection.
• HCV genotype co-infection with any other HCV genotype.
• Use of contraindicated medications within 2 weeks or 10 half-lives of dosing.